[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

February 2019 | 47 pages | ID: 2255A8680F2EN
VPAResearch

US$ 1,979.00 US$ 2,199.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The ongoing clinical trial research report- “2019 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials Study” analyzes the current scenario of all active Vaso-Occlusive Crisis Associated With Sickle Cell Disease trials across the world. The report presents top level analysis of global Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Vaso-Occlusive Crisis Associated With Sickle Cell Disease trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials by-
  • Region (Asia Pacific, Europe, Middle East Africa and Americas)
  • Countries
  • Trial Phase
  • Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
  • Type of the trial (Interventional, Observational)
  • Sponsor Type (Companies, Universities, Government Bodies etc)
  • Enrollment across types, sponsor types, geographies, current status and phases
The report also identifies the potential drug candidates under development for treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease on the basis of intervention type ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease trials.

The research work is prepared through extensive and continuous research on Vaso-Occlusive Crisis Associated With Sickle Cell Disease trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:
  • All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Vaso-Occlusive Crisis Associated With Sickle Cell Disease patients are identified
  • The report includes panorama of ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
  2.2.1 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Region
  2.2.2 Average Enrollment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials
  2.2.3 Companies participating in Ongoing Trials
  2.2.4 Drugs under Study for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Treatment, 2019

3. REGION WISE VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE CLINICAL TRIALS

3.1 Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Country
3.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Country
3.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Country
3.4 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Country
3.5 South and Central America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials by Country

4. VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials
4.2 Phase wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials
4.3 Trial Status wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials
4.4 Trial Type wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials

5. VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials by Year
5.2 Average Enrollment in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials by Phase
5.3 Average Enrollment in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials by Status
5.4 Average Enrollment in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE CLINICAL TRIALS

6.1 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials by Sponsor Type
6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials- Phase
7.2 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials- Phase
7.3 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials- Phase
7.4 Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

LIST OF FIGURES

Figure 1: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Figure 5: Europe – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Figure 7: North America – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Figure 9: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Phase
Figure 10: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Trial Status
Figure 11: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Type
Figure 12: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Sponsor Type
Figure 13: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials by Leading Sponsors
Figure 14: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Phase
Figure 15: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Trial Status
Figure 16: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Type
Figure 17: Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Average Enrolment by Type of Sponsors
Figure 18: Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

LIST OF TABLES

Table 1: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Ongoing Clinical Trials Snapshot- 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Table 5: Europe – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Table 7: North America – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Ongoing Vaso-Occlusive Crisis Associated With Sickle Cell Disease Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Phase
Table 15: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Trial Status
Table 16: Vaso-Occlusive Crisis Associated With Sickle Cell Disease Average Enrollment by Type
Table 17: Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Average Enrolment by Type of Sponsors
Table 18: Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Enrolment by Leading Sponsors


More Publications